Healthcare / Diagnostics & ResearchBSE
$410.00
-9.40 (-2.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-128.5M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.8B
P/E
31.3x
↑EV/EBITDA
19.0x
↑ROE
9.6%
↑Gross Margin
86.6%
↑Debt/Equity
0.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+86.7%
FCF CAGR
—
FCF margin
-25.3%
FCF / Net income
-2.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.25B · net income $146.0M · FCF $-315.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.25B | $1.25B | $702.3M | $291.8M | $191.4M |
| Net Income | $146.0M | $146.0M | $63.0M | $43.1M | $29.4M |
| EBITDA | $298.1M | $298.1M | $167.6M | $81.3M | $54.8M |
| EPS | — | — | 7.08 | 7.46 | 3.99 |
| Gross Margin | 86.6% | 86.6% | 85.5% | 80.2% | 77.8% |
| Operating Margin | 18.2% | 18.2% | 17.1% | 23.1% | 23.9% |
| Net Margin | 11.7% | 11.7% | 9.0% | 14.8% | 15.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.61 | 0.61 | 0.58 | 0.38 | 2.37 |
| Current Ratio | 1.04 | 1.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-315.5M | $-315.5M | $-128.5M | $-48.3M | $-101.0M |
| Returns | |||||
| ROE | 9.6% | 9.6% | 7.3% | 13.3% | 29.8% |
| Valuation | |||||
| P/E | 31.35 | 31.35 | 36.02 | 21.05 | — |
| EV/EBITDA | 18.96 | 18.96 | 16.28 | 12.60 | — |
| P/B | 3.13 | 3.13 | 2.61 | 2.79 | — |
| Growth & Yield | |||||
| Revenue Growth | 77.3% | 77.3% | 140.6% | 52.5% | — |
| EPS Growth | — | — | -5.1% | 86.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.6%
Start / end P/E
n/dx → n/dx
EPS bridge
7.08 → n/d
Residual
+34.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.